[Form 4] ANI Pharmaceuticals, Inc. Insider Trading Activity

Rhea-AI Filing Summary

ANI Pharmaceuticals insider transaction: The company's President & CEO and director, Nikhil Lalwani, reported selling 56,960 shares of ANI Pharmaceuticals, Inc. (ANIP) on 08/12/2025 at a weighted average sale price of $85.93 per share. After the sale, he beneficially owns 411,219 shares, reported as directly owned.

The Form 4 was signed by attorney-in-fact Meredith W. Cook on 08/14/2025 and notes the shares were sold in multiple trades with execution prices ranging from $84.40 to $87.47. No derivative transactions or other securities classes are reported.

Positive

• Clear disclosure of the transaction including weighted average price and price range
• Substantial remaining ownership of 411,219 shares after the sale, indicating continued insider stake
• Form filed by one reporting person and signed by attorney-in-fact, showing procedural compliance

Negative

• Insider sale of 56,960 shares, a notable reduction in holdings
• No explanation provided for the disposition beyond sale execution details

Insights

Financial Analyst

TL;DR CEO sold 56,960 shares at a weighted average of $85.93, retaining 411,219 shares.

The sale is a straightforward disclosure of insider liquidation. The reported weighted average price and the stated range ($84.40 to $87.47) provide clear execution context. Retaining 411,219 shares indicates continued substantial ownership, which may partially mitigate market concerns about the sale's significance. There are no derivative transactions disclosed, and the filing appears complete and timely.

Corporate Governance Expert

TL;DR Director and CEO completed a multi-trade sale; filings reflect compliance with Section 16 reporting.

The Form 4 identifies the reporting person as both President & CEO and director, and shows a single-day disposition reported within standard timelines. The filing includes an attorney-in-fact signature, indicating procedural adherence. From a governance perspective, the disclosure fulfills transparency requirements; no related-party or derivative complexities are disclosed.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Lalwani Nikhil

(Last) (First) (Middle)

C/O ANI PHARMACEUTICALS, INC.

210 MAIN STREET WEST

(Street)

BAUDETTE MN 56623

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ANI PHARMACEUTICALS INC [ ANIP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	PRESIDENT & CEO

3. Date of Earliest Transaction (Month/Day/Year)
08/12/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/12/2025		S		56,960	D	$85.93(1)	411,219	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The shares were sold in multiple trades at prices ranging from $84.40 to $87.47. The price reported above reflects the weighted average sales price.

Remarks:

	/s/ Nikhil Lalwani, by attorney-in-fact Meredith W. Cook	08/14/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did ANIP insider Nikhil Lalwani disclose on Form 4?

The Form 4 reports a sale of 56,960 shares on 08/12/2025 at a weighted average price of $85.93, leaving him with 411,219 shares beneficially owned.

At what prices were ANIP shares sold in the reported transaction?

The shares were sold in multiple trades at prices ranging from $84.40 to $87.47; the weighted average sale price reported is $85.93.

Does the Form 4 report any option exercises or derivative transactions for ANIP?

No. Table II for derivative securities shows no transactions reported; only a non-derivative common stock sale is disclosed.

Who signed the Form 4 for the ANIP filing?

The Form 4 was signed by /s/ Nikhil Lalwani, by attorney-in-fact Meredith W. Cook on 08/14/2025.

What is the reporting person's role at ANI Pharmaceuticals (ANIP)?

The reporting person is identified as both a Director and the President & CEO of ANI Pharmaceuticals.